Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Artificial Intelligence
CRO
FDA qualifies 1st AI drug development tool in MASH
AIM-NASH is meant to help score the different stages of liver biopsy, including fat infiltration, inflammation and scarring.
Gabrielle Masson
Dec 9, 2025 12:12pm
Novartis pens $1.7B atopic disease pact with British biotech
Dec 9, 2025 3:57am
FDA clears Resmed AI for personalizing CPAP settings
Dec 8, 2025 11:50am
GE HealthCare, Mayo to tap digital twins for radiation therapy
Dec 4, 2025 12:06pm
FDA adopts agentic artificial intelligence in latest AI push
Dec 1, 2025 5:33pm
Chronic stress you can see—on a CT scan
Dec 1, 2025 10:40am
